Mekostest 36 (Bacitracin, Hydrocortisone Butyrate, Tixocortol Pivalate, Bronopol, Budesonide, Chlorquinaldol, Clio)

Bacitracin inhibits bacterial cell‑wall synthesis by interfering with the dephosphorylation of bactoprenol, a carrier molecule essential for peptidoglycan assembly. This action stops bacterial growth, allowing the immune system to clear the infection. In the combination product, bacitracin works alongside corticosteroids and antiseptics to provide a multi‑modal therapeutic effect.

The dosage of Mekostest 36 is determined by the prescribing healthcare professional based on the specific indication, severity, patient age and the size of the affected area. Typically, a thin layer is applied to the cleaned skin once or twice daily, but exact instructions should always follow the prescriber's order.

Safety data for Mekostest 36 in pregnancy and lactation are limited. Because the product contains corticosteroids and multiple antimicrobial agents, it should be used only if the potential benefit outweighs any possible risk. Pregnant or nursing women should discuss use with their physician before applying the medication.

To request Mekostest 36, visit the product page on gnhindia.com, enter the required quantity and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Mekostest 36 offers a broader spectrum than single‑agent topical antibiotics because it combines bacitracin with additional corticosteroids, antiseptics and an antifungal component. This multi‑ingredient approach can address mixed bacterial‑fungal infections and inflammatory skin conditions in one formulation, whereas many alternatives target only one type of pathogen or inflammation.

Store Mekostest 36 at room temperature, preferably below 25 °C. Keep the tube or container tightly closed, protect it from moisture and direct sunlight, and retain it in the original packaging until use. Do not freeze the product, and discard any portion that appears discoloured or contaminated.

Mekostest 36 is applied topically to the affected skin area. Clean and gently dry the area, then spread a thin, even layer of the cream or ointment as directed by the prescriber, usually once or twice daily. Wash hands before and after application unless the hands are the treatment site.

Serious risks include allergic reactions such as hives, swelling or anaphylaxis, secondary infections due to resistant organisms, and systemic corticosteroid effects like adrenal suppression when used over large body surfaces or for prolonged periods. Patients should seek immediate medical attention if they experience severe skin reactions or systemic symptoms.

Mekostest 36 should be avoided in individuals with known hypersensitivity to any of its components, including bacitracin, corticosteroids, bronopol, chlorquinaldol or clioquinol. It is also contraindicated on extensive broken skin, on the face or mucous membranes unless specifically prescribed, and in patients receiving systemic immunosuppressive therapy without medical supervision.